Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter

Where this information about bisphosphonates comes from

Nurse and patients talking about cancer

This page tells you about the major sources of information that we use to put together this section.



All our information is checked by cancer specialists. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had bisphosphonates, live in the UK and would like to become a patient reviewer, you can write to us by clicking on the 'contact us' button on the right hand side of this page.



Electronic Medicines Compendium

British National Formulary

National Institute of Clinical Excellence Guidelines

Scottish Intercollegiate Guidelines Network

National Cancer Institute - USA

PubMed Central - National Institute of Health Medical Archive of Science Literature



Handbook of Cancer Chemotherapy (8th edition)
Skeel RT and Khleif SN
Lippincott Williams and Wilkins, 2011

Principles and practice of oncology (8th edition)
De Vita VT, Hellman S and Rosenberg SA
Lippincott, Williams and Wilkins, 2008



Reviews and articles

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Michael Pazianas, Cyrus Cooper, F Hal Ebetino, R Graham G Russell. Therapeutics and Clinical Risk Management 
2010:6 325–343

Bisphosphonates in multiple myeloma. (Cochrane review). R Mhaskar, J Redzepovic, K Wheatley, OAC Clark, B Miladinovic, A Glasmacher, A Kumar, B Djulbegovic B. Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.

Emerging role of bisphosphonates in the clinic - anti tumor activity and prevention of metastasis to bone. Lipton A. Cancer Treatment Review. 2008;34 Suppl 1:S25-30.

Zoledronic acid in the management of metastatic bone disease. Polascik TJ, Mouraviev V. Therapeutic Clinical Risk Managagement. 2008 Feb;4(1):261-8.

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Cancer. 2008 Jul 1;113(1):193-201.

Bisphosphonates and other bone agents for breast cancer. (Cochrane review). Wong MHF, Stockler MR, Pavlakis N. Database of Systematic Reviews 2012, Issue 2. Art. No.: CD003474. DOI: 10.1002/14651858.CD003474.pub3.

Bisphosphonates for advanced prostate cancer. (Cochrane review). KK Yuen, M Shelley, WM Sze, TJ Wilt, M Mason. Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006250. DOI: 10.1002/14651858.CD006250.

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Migliorati Prof. Cesar A, Siegel Prof Michael A, and Elting Prof Linda S. Lancet Oncology, Volume 7, Issue 6, June 2006, Pages 508-514.

Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Costa L, Lipton A, Coleman RE. Supportive Cancer Therapy. 2006 Apr 1;3(3):143-53.


Specialist reviewers

Ms Debbie Wright

We would like to thank the pharmaceutical manufacturers who have answered our questions during the compilation of this information. 

Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 17 November 2012